Suicide attempt in ulcerative colitis patient after 4 months of infliximab therapy - A case report

被引：20

作者：

Eshuis, E. J. ^{[1
,2
]}

Magnin, K. M. M. Y. ^{[3
]}

Stokkers, P. C. F. ^{[2
]}

Bemelnnan, W. A. ^{[1
]}

Bartelsman, J. ^{[1
,2
]}

机构：

[1] Acad Med Ctr, Dept Gastroenterol & Hepatol, NL-1100 DD Amsterdam, Netherlands

[2] Acad Med Ctr, Dept Surg, NL-1100 DD Amsterdam, Netherlands

[3] Acad Med Ctr, Dept Psychiat, NL-1100 DD Amsterdam, Netherlands

来源：

JOURNAL OF CROHNS & COLITIS | 2010年 / 4卷 / 05期

关键词：

IBD; Infliximab; Side effects; Depression; Suicidal attempt; Ulcerative colitis; INFLAMMATORY-BOWEL-DISEASE; RISK;

D O I：

10.1016/j.crohns.2010.04.001

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

In the summary of product characteristics of infliximab (IFX), psychiatric side effects are reported to be rare, and in literature only limited data exist This report presents a case of a patient with ulcerative colitis who developed a depression with psychotic symptoms during IFX therapy and made a suicide attempt 4 months after the initiation of therapy Although the time between start of IFX therapy and onset of symptoms could suggest a correlation, this, of course, does not prove that IFX was the causative factor for his depression and suicide attempt (C) 2010 Published by Elsevier B V on behalf of European Crohns and Colitis Organisation

引用

页码：591 / 593

页数：3

共 11 条

[1]

Eshuis Emma J, 2009, Expert Rev Gastroenterol Hepatol, V3, P219, DOI 10.1586/egh.09.19

[2] Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis [J].

Feldmann, M ;

Elliott, MJ ;

Woody, JN ;

Maini, RN .

ADVANCES IN IMMUNOLOGY, VOL 64, 1997, 64 :283-350

[3] Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? [J].

Hanauer, Stephen B. .

GUT, 2007, 56 (09) :1181-1183

[4] Panic attack with suicide: An exceptional adverse effect of infliximab [J].

Roblin, Xavier ;

Oltean, Paula ;

Heluwaert, Frederic ;

Bonaz, Bruno .

DIGESTIVE DISEASES AND SCIENCES, 2006, 51 (06) :1056-1056

[5] Infliximab for induction and maintenance therapy for ulcerative colitis [J].

Rutgeerts, P ;

Sandborn, WJ ;

Feagan, BG ;

Reinisch, W ;

Olson, A ;

Johanns, J ;

Travers, S ;

Rachmilewitz, D ;

Hanauer, SB ;

Lichtenstein, GR ;

de Villiers, WJS ;

Present, D ;

Sands, BE ;

Colombel, JF .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (23) :2462-2476

[6] Hepatosplenic T cell lymphoma in inflammatory bowel disease [J].

Shale, Matthew ;

Kanfer, Ed ;

Panaccione, Remo ;

Ghosh, Subrata .

GUT, 2008, 57 (12) :1639-1641

[7] Risk factors for opportunistic infections in patients with inflammatory bowel disease [J].

Toruner, Murat ;

Loftus, Edward V., Jr. ;

Harmsen, W. Scott ;

Zinsmeister, Alan R. ;

Orenstein, Robert ;

Sandborn, William J. ;

Colombel, Jean-Frederic ;

Egan, Laurence J. .

GASTROENTEROLOGY, 2008, 134 (04) :929-936

[8] TREATMENT OF CROHNS-DISEASE WITH ANTITUMOR NECROSIS FACTOR CHIMERIC MONOCLONAL-ANTIBODY (CA2) [J].

VANDULLEMEN, HM ;

VANDEVENTER, SJH ;

HOMMES, DW ;

BIJL, HA ;

JANSEN, J ;

TYTGAT, GNJ ;

WOODY, J .

GASTROENTEROLOGY, 1995, 109 (01) :129-135

[9] Glucocorticoids Mood, Memory, and Mechanisms [J].

Wolkowitz, Owen M. ;

Burke, Heather ;

Epel, Elissa S. ;

Reus, Victor L. .

GLUCOCORTICOIDS AND MOOD CLINICAL MANIFESTATIONS, RISK FACTORS, AND MOLECULAR MECHANISMS, 2009, 1179 :19-40

[10] Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis [J].

Yang, Z. ;

Wu, Q. ;

Wu, K. ;

Fan, D. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 31 (04) :486-492

← 1 2 →